Spyre Therapeutics, Inc. Insider Selling: Scott Burrows L Trims Stake

A Form 4 filed with the SEC shows Scott Burrows L, CFO at Spyre Therapeutics, Inc. (SYRE), sold 25,000 shares of company stock on 2026-09-30.

The transaction was executed at a price of $90.47 per share, for a total value of approximately $2.26 million.

Under SEC rules, corporate insiders — officers, directors, and holders of more than 10% of a company's shares — are required to report changes in their ownership within two business days of the transaction via Form 4.

Sales by insiders often reflect routine portfolio management or pre-scheduled trading plans rather than a view on the company's prospects.